Comparable stake leader
Nant Capital, LLC
SEC ownership of PDS Biotechnology Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001472091.
Disclosed value leader
Nant Capital, LLC
Comparable rows
50/50
Latest evidence
14 Sep 2026
- Public ticker
- PDSB on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Nant Capital, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Nant Capital, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
14 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001472091
- Issuer location
- Princeton, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PDS Biotechnology Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Nant Capital, LLC
Disclosed value leader
Nant Capital, LLC
Comparable rows
50/50
Latest evidence
14 Sep 2026
3/4/5
13D/G
13F
Lead comparable stake: 20%
13D/G row: Nant Capital, LLC
Showing 1-8 of 50 holder rows.
Quick read
Nant Capital, LLC leads the comparable SEC ownership view at 20%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Nant Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Nant Capital, LLC
20%
Patrick Soon-Shiong
13%
Janetta Trochimiuk
0%
VANGUARD CAPITAL MANAGEMENT LLC
1.7%
Focus Partners Wealth
0.63%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Nant Capital, LLC |
3/4/5
13D/G
10%+ Owner
|
20%
from 13D/G
|
$11,458,999
13,005,334 shares
|
— | 14 Sep 2026 |
| Patrick Soon-Shiong |
3/4/5
Director, 10%+ Owner
|
13%
|
$11,458,999
13,005,334 shares
|
— | 14 Sep 2026 |
| Janetta Trochimiuk |
3/4/5
Principal Accounting Officer
|
0%
|
$990
1,124 shares
|
— | 12 Sep 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
1.7%
|
$1,497,097
1,699,315 shares
|
— | 30 Jun 2026 |
| Focus Partners Wealth |
13F
Company
|
0.63%
|
$565,822
642,177 shares
|
— | 30 Jun 2026 |
| Quantinno Capital Management LP |
13F
Company
|
0.63%
|
$565,822
642,177 shares
|
— | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
0.59%
|
$535,391
607,639 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.57%
|
$517,410
587,139 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 03 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to PDS Biotechnology Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
Nant Capital, LLC
Net 12M change
$0
Latest report
14 Sep 2026
Recent insider transactions for PDS Biotechnology Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Frank Bedu-Addo | PDSB | Employee Stock Option (Right to Buy) | Award | 548,782 | 548,782 | 12 Jan 2026 | Direct | |||
| Gregory Conn | PDSB | Employee Stock Option (Right to Buy) | Award | 150,000 | 150,000 | 12 Jan 2026 | Direct | |||
| Kirk V Shepard | PDSB | Employee Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 12 Jan 2026 | Direct | |||
| Lars Boesgaard | PDSB | Employee Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 12 Jan 2026 | Direct | |||
| Spencer D. Brown | PDSB | Employee Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 12 Jan 2026 | Direct | |||
| Stephan Toutain | PDSB | Employee Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 12 Jan 2026 | Direct | |||
| Gregory Gene Freitag | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct | |||
| Ilian Iliev | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct | |||
| Kamil Ali-Jackson | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct | |||
| Otis W. Brawley | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct | |||
| Stephen C. Glover | PDSB | Employee Stock Option (Right to Buy) | Award | 54,876 | 54,876 | 12 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.